Complete financial analysis of Codiak BioSciences, Inc. (CDAK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codiak BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shanghai Pret Composites Co., Ltd. (002324.SZ) Income Statement Analysis – Financial Results
- ZERO Co., Ltd. (9028.T) Income Statement Analysis – Financial Results
- Leedarson IoT Technology Inc. (605365.SS) Income Statement Analysis – Financial Results
- Pancontinental Energy NL (PCOGF) Income Statement Analysis – Financial Results
- Kvutzat Acro Ltd (ACRO.TA) Income Statement Analysis – Financial Results
Codiak BioSciences, Inc. (CDAK)
About Codiak BioSciences, Inc.
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 22.94M | 2.92M | 388.00K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 22.94M | 2.92M | 388.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 64.86M | 73.98M | 59.50M | 36.54M |
| General & Administrative | 27.63M | 19.85M | 21.04M | 9.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.63M | 19.85M | 21.04M | 9.90M |
| Other Expenses | 0.00 | 906.00K | 992.00K | 0.00 |
| Operating Expenses | 92.48M | 93.83M | 80.54M | 46.44M |
| Cost & Expenses | 92.48M | 93.83M | 80.54M | 46.44M |
| Interest Income | 22.00K | 253.00K | 1.50M | 1.36M |
| Interest Expense | 2.70M | 1.91M | 300.00K | 0.00 |
| Depreciation & Amortization | 6.42M | 1.16M | 5.26M | 1.73M |
| EBITDA | -61.33M | -89.76M | -74.89M | -42.82M |
| EBITDA Ratio | -267.39% | -3,079.21% | -19,301.03% | 0.00% |
| Operating Income | -69.55M | -90.92M | -80.15M | -46.44M |
| Operating Income Ratio | -303.24% | -3,118.97% | -20,657.73% | 0.00% |
| Total Other Income/Expenses | 32.39M | -747.00K | 2.19M | 1.90M |
| Income Before Tax | -37.16M | -91.67M | -77.96M | -44.54M |
| Income Before Tax Ratio | -162.01% | -3,144.60% | -20,092.78% | 0.00% |
| Income Tax Expense | 4.48M | -2.73M | 1.29M | 1.90M |
| Net Income | -41.63M | -88.93M | -79.25M | -44.54M |
| Net Income Ratio | -181.53% | -3,050.81% | -20,425.77% | 0.00% |
| EPS | -1.91 | -14.04 | -6.03 | -3.40 |
| EPS Diluted | -1.91 | -14.04 | -6.03 | -3.40 |
| Weighted Avg Shares Out | 21.79M | 6.33M | 13.13M | 13.11M |
| Weighted Avg Shares Out (Dil) | 21.79M | 6.33M | 13.13M | 13.11M |
Codiak Announces Proposed Public Offering of Common Stock
Codiak Reports Additional Positive Phase 1 Results for exoIL-12™ Confirming Local Pharmacology and Dose Selection for Safety and Efficacy Trial in Early-Stage Cutaneous T Cell Lymphoma (CTCL) Patients
Codiak's Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers
Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress
Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity
Codiak Announces Pricing of Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports